Back to News
Market Impact: 0.25
Cardiff's Onvansertib Wins FDA Orphan Drug Designation For Rare Blood Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA granted orphan drug designation to Cardiff Oncology's onvansertib for chronic myelomonocytic leukemia. This is a regulatory milestone, not an approval, and the article provides no financial figures or reported market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CRDF0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- OpenAI disables internet access during model training while Anthropic issues another mea culpa
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Write an Investment Memo with AI: A Decision-Record Template
- Best AI to Write Earnings Notes for Sell-Side Analysts